CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Prospective evaluation of cardiac safety in breast cancer patients after adjuvant treatment with epirubicin, cyclophosphamide, doxetaxel and with or without trastuzumab: A single center experience
DOI 10.1055/s-0035-1560003
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Puppe, D van Ooyen, J Neise, F Thangarajah, C Eichler, R Pfister, S Krämer, P Mallmann, M Wirtz, G Michels
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Anticancer drugs can cause cardiotoxicity. Chemotherapy with antracyclines is associated with electrocardiographic alterations including prolongation of the corrected QT (QTc) interval with the risk of life threatening arrhythmias. Among the new targeted therapies QTc aberrations were reported upon treatment with anti HER2/neu agents. The combination of the antracycline epirubicin and monoclonal antibody trastuzumab…
Zitieren
Zitierempfehlung
J Puppe, D van Ooyen, J Neise, F Thangarajah, C Eichler, R Pfister, S Krämer, P Mallmann, M Wirtz, G Michels (2015) Prospective evaluation of cardiac safety in breast cancer patients after adjuvant treatment with epirubicin, cyclophosphamide, doxetaxel and with or without trastuzumab: A single center experience. Geburtshilfe und Frauenheilkunde (08). https://doi.org/10.1055/s-0035-1560003
Mit CareLit weiterarbeiten